289 related articles for article (PubMed ID: 31929797)
1. mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance.
Woo Y; Lee HJ; Jung YM; Jung YJ
J Oncol; 2019; 2019():5956867. PubMed ID: 31929797
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin Promotes ROS-Mediated Cell Death
Woo Y; Lee HJ; Kim J; Kang SG; Moon S; Han JA; Jung YM; Jung YJ
Front Oncol; 2021; 11():665420. PubMed ID: 33959512
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma
Yu CC; Hung SK; Lin HY; Chiou WY; Lee MS; Liao HF; Huang HB; Ho HC; Su YC
Oncotarget; 2017 Sep; 8(40):68641-68653. PubMed ID: 28978144
[TBL] [Abstract][Full Text] [Related]
4. Stathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells.
Zhang X; Ji J; Yang Y; Zhang J; Shen L
Onco Targets Ther; 2016; 9():2565-74. PubMed ID: 27199567
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
6. ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma.
Chen Q; Zheng W; Zhu L; Yao D; Wang C; Song Y; Hu S; Liu H; Bai Y; Pan Y; Zhang J; Guan J; Shao C
Front Cell Dev Biol; 2020; 8():232. PubMed ID: 32373608
[TBL] [Abstract][Full Text] [Related]
7. Targeting the AKT/cyclin D1 pathway to overcome intrinsic and acquired radioresistance of tumors for effective radiotherapy.
Shimura T
Int J Radiat Biol; 2017 Apr; 93(4):381-385. PubMed ID: 27910734
[TBL] [Abstract][Full Text] [Related]
8. Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance.
Liu S; Imani S; Deng Y; Pathak JL; Wen Q; Chen Y; Wu J
Onco Targets Ther; 2020; 13():6037-6050. PubMed ID: 32606809
[TBL] [Abstract][Full Text] [Related]
9. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.
Marampon F; Codenotti S; Megiorni F; Del Fattore A; Camero S; Gravina GL; Festuccia C; Musio D; De Felice F; Nardone V; Santoro AN; Dominici C; Fanzani A; Pirtoli L; Fioravanti A; Tombolini V; Cheleschi S; Tini P
J Cancer Res Clin Oncol; 2019 Apr; 145(4):881-893. PubMed ID: 30701326
[TBL] [Abstract][Full Text] [Related]
10. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.
Dumont FJ; Bischoff P
Curr Cancer Drug Targets; 2012 Oct; 12(8):899-924. PubMed ID: 22831276
[TBL] [Abstract][Full Text] [Related]
11. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
12. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
13. Annexin A1: a new biomarker for predicting nasopharyngeal carcinoma response to radiotherapy.
Zeng GQ; Cheng AL; Tang J; Li GQ; Li MX; Qu JQ; Cao C; Liao L; Xiao ZQ
Med Hypotheses; 2013 Jul; 81(1):68-70. PubMed ID: 23660133
[TBL] [Abstract][Full Text] [Related]
14. Nrf2 is a potential therapeutic target in radioresistance in human cancer.
Zhou S; Ye W; Shao Q; Zhang M; Liang J
Crit Rev Oncol Hematol; 2013 Dec; 88(3):706-15. PubMed ID: 24126138
[TBL] [Abstract][Full Text] [Related]
15. Lysosomes contribute to radioresistance in cancer.
Zhang X; Wang J; Li X; Wang D
Cancer Lett; 2018 Dec; 439():39-46. PubMed ID: 30217567
[TBL] [Abstract][Full Text] [Related]
16. Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy.
Shimura T; Kakuda S; Ochiai Y; Kuwahara Y; Takai Y; Fukumoto M
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):540-8. PubMed ID: 21398050
[TBL] [Abstract][Full Text] [Related]
17. Exosomes in Cancer Radioresistance.
Ni J; Bucci J; Malouf D; Knox M; Graham P; Li Y
Front Oncol; 2019; 9():869. PubMed ID: 31555599
[TBL] [Abstract][Full Text] [Related]
18. Recent progress of the tumor microenvironmental metabolism in cervical cancer radioresistance.
Zhou J; Lei N; Tian W; Guo R; Chen M; Qiu L; Wu F; Li Y; Chang L
Front Oncol; 2022; 12():999643. PubMed ID: 36313645
[TBL] [Abstract][Full Text] [Related]
19. Potential Applications of NRF2 Modulators in Cancer Therapy.
Panieri E; Buha A; Telkoparan-Akillilar P; Cevik D; Kouretas D; Veskoukis A; Skaperda Z; Tsatsakis A; Wallace D; Suzen S; Saso L
Antioxidants (Basel); 2020 Feb; 9(3):. PubMed ID: 32106613
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
